Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.47 |
| ▸ | NCF1 | P14598 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP4 | P49662 | 1/20 | 0.41 |
| ▸ | CASP5 | P51878 | 1/20 | 0.41 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20640242 | 0.84 | CNR2 (0.41) | CYP1A2HRH4ALDH1A1JAK2JAK1 | |
| SCHEMBL30343272 | 0.84 | ADRB1 (0.50) | CYP1A2ADRB1NCF1CHRNB2CHRNA4 | |
| SCHEMBL1460126 | 0.80 | ALDH1A1 (0.58) | CYP1A2ALDH1A1CASP1 | |
| SCHEMBL22115009 | 0.80 | ALDH1A1 (0.38) | CYP1A2ALDH1A1JAK2JAK1TYK2 | |
| SCHEMBL21768458 | 0.79 | OPRM1 (0.46) | JAK2JAK1TYK2JAK3 | |
| Hydrochloric Acid SCHEMBL25311811 | 0.79 | CHRNB2 (0.53) | CYP1A2ADRB1NCF1CHRNB2CHRNA4 | |
| SCHEMBL21652561 | 0.79 | CYP1A2 (0.46) | CYP1A2ADRB1NCF1CHRNB2CHRNA4 | |
| SCHEMBL1740261 | 0.78 | TLR8 (0.40) | CYP1A2ALDH1A1JAK2JAK1TYK2 | |
| SCHEMBL15205378 | 0.78 | ALDH1A1 (0.40) | CYP1A2ALDH1A1JAK2JAK1TYK2 | |
| SCHEMBL23560716 | 0.76 | TAAR1 (0.47) | CYP1A2ADRB1NCF1JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2480529-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| CN-102574788-A | Indole derivatives as crac modulators | HOFFMANN LA ROCHE | 2012-07-11 | — | — | CN | disclosed |
| WO-2011036130-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ORAI1, RYR2, CACNA1E | CYP1A2 1233/4885ADRB1 71/4885NCF1 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.